Increasingly, contract development and manufacturing organizations (CDMOs) like Vetter are acting as the interface between small biotech firms and large drug manufacturers
Flexibility, responsiveness and operational excellence are being demanded by drug developers. The challenge faced by companies like Vetter Pharma International is to deliver these to customers. Oskar Gold, notes that Vetter believes that partnership is always the key to success, with operational excellence being decisive in both the development and commercial phases.
“Particularly in the early drug development phases, a number of issues that can affect the entire development project scope can arise and thus flexibility is critical,” Gold says. “Also, it is important that a sponsor and service provider with a common target in mind act as one to successfully perform a drug development project that can get the drug on the market as fast as possible, where it can improve or even save patient lives.”
Listen to the video interview with Oskar Gold of Vetter discussing current market developments and their multifaceted impacts.